Every year, thousands of men with low testosterone are prescribed clomiphene citrate — Clomid — as a fertility-sparing alternative to testosterone replacement. It works. Testosterone rises. Sperm production continues. But many men feel worse: low mood, brain fog, reduced libido, emotional blunting. The drug that fixes the number often fails the patient. The reason has been hiding in the pharmacology all along.
Clomiphene citrate is not one drug. It is two.
Two Isomers, Opposite Effects
Clomiphene citrate (CC) is a racemic mixture of two geometric isomers:
- Enclomiphene (trans-clomiphene, ~62% of the mixture) — an estrogen receptor antagonist. This is the active isomer. It blocks estrogen feedback at the hypothalamus and pituitary, causing LH and FSH to rise, which stimulates the testes to produce more testosterone.
- Zuclomiphene (cis-clomiphene, ~38% of the mixture) — an estrogen receptor agonist. This isomer activates estrogen receptors. In men, this is counterproductive — it works against the very mechanism that makes the drug useful.
One isomer raises testosterone. The other acts like estrogen. They are packaged together in every Clomid tablet.
This would matter less if both isomers behaved the same way in the body. They don't.
The Accumulation Problem
In 2017, Helo and colleagues at Baylor College of Medicine published a study that should have changed how we think about clomiphene in men. They measured serum concentrations of both isomers in 15 men taking CC for hypogonadism. What they found was striking.
Enclomiphene has a half-life of approximately 8 hours. Zuclomiphene's half-life exceeds 40 hours — five times longer. Over weeks of daily dosing, zuclomiphene accumulates relentlessly while enclomiphene reaches steady state quickly.
After six or more weeks of therapy, the serum ratio of zuclomiphene to enclomiphene was 20:1.
Schematic based on Helo et al. 2017. Enclomiphene (t½ ~8h) reaches steady state within days. Zuclomiphene (t½ >40h) accumulates continuously, reaching 20x the enclomiphene concentration by week 6.
Think about what this means. A man taking Clomid for hypogonadism is, within weeks, primarily taking an estrogen agonist. The anti-estrogenic isomer that drives testosterone production is a minor component of what's actually circulating.
Miller et al. (2019) confirmed the persistence problem from the other direction. After men stopped clomiphene, enclomiphene became undetectable by day 44. Zuclomiphene was still measurable at 15.12 ng/mL on day 58 — and in urine, zuclomiphene remained detectable for 121 to over 261 days. Nearly nine months of estrogenic residue from a drug that was supposed to be anti-estrogenic.
This pharmacokinetic mismatch likely explains most of clomiphene's tolerability problems in men:
- Mood changes and emotional blunting — estrogen receptor activation in the brain
- Decreased libido despite rising testosterone — the estrogenic signal overriding the androgenic one
- Gynecomastia — direct estrogenic breast tissue stimulation
- Visual disturbances — reported in 1–2% of CC users; case reports include optic neuropathy after just 14 days
The 2025 meta-analysis in Archives of Endocrinology and Metabolism captured a telling detail: CC increases estradiol by 17.50 pg/mL. Enclomiphene alone decreases estradiol by 5.92 pg/mL. Same class of drug. Opposite estrogen effects. The zuclomiphene contamination isn't theoretical — it's measurable.
Enter Enclomiphene: The Drug That Should Have Been
If zuclomiphene is the problem, the solution seems obvious: give patients pure enclomiphene. This was the logic behind Androxal, developed by Repros Therapeutics as the isolated trans-isomer of clomiphene for male secondary hypogonadism.
The clinical data was compelling. Wiehle et al. (2013, BJU International) showed that enclomiphene 25 mg daily achieved mean total testosterone of 604 ng/dL and LH of 13.1 IU/L in hypogonadal men — restoring testosterone while driving gonadotropins up, exactly the opposite of TRT. Unlike TRT, sperm counts were maintained or improved.
The 2025 SERM meta-analysis confirmed the broader picture: across 10 randomized controlled trials with 819 patients, SERMs (clomiphene and enclomiphene) boosted total testosterone by a mean of 273.76 ng/dL (95% CI: 191.87–355.66, p<0.01) while significantly increasing LH and FSH. This testosterone increase is comparable to topical testosterone gel — but with preserved fertility.
The 5th International Consultation on Sexual Medicine (ICSM 2024), published in Sexual Medicine Reviews in October 2025 by Khera, Morgentaler, Salonia and colleagues, produced 29 consensus recommendations on male hypogonadism. Their position on SERMs was clear: enclomiphene is preferred over racemic clomiphene when available, with 82% fewer adverse events. Recommended dosing: 12.5–25 mg daily.
Baylor College of Medicine's own retrospective comparison confirmed: enclomiphene produced comparable testosterone increases with significantly fewer side effects — less mood disruption, less libido reduction, fewer energy complaints.
The Regulatory Tragedy
If enclomiphene works as well as clomiphene with dramatically fewer side effects, why isn't it FDA-approved? The answer is one of the stranger regulatory stories in recent endocrinology.
Androxal's failure was not clinical. It was methodological and regulatory.
Repros Therapeutics spent years developing Androxal. They completed Phase 3 trials. The NDA was accepted. A PDUFA decision date was set. Then, weeks before the advisory committee meeting, the FDA cancelled it — citing questions about the bioanalytical method used to measure enclomiphene levels in the pivotal trials.
Not efficacy. Not safety. Not a failed endpoint. The FDA's concern was about whether the analytical assay used to measure drug levels in the study was properly validated. The Complete Response Letter in December 2015 added that the study design was "no longer adequate" — likely reflecting the FDA's post-2015 tightening of what constitutes a valid hypogonadism indication, influenced by broader concerns about testosterone product cardiovascular safety that were playing out around the same time (the TRAVERSE trial era).
The European Medicines Agency (EMA) rejected the application in January 2018. By April 2021, Repros had discontinued development for all indications.
Androxal failed not because enclomiphene doesn't work, but because the regulatory environment shifted beneath it. The drug fell into a gap between its clinical promise and the analytical/regulatory standards of its era.
The Legacy Effect: A Clue About Pulsatility
One of the most intriguing findings from the Androxal program connects to a theme that keeps appearing across hypogonadism research: pulsatility.
Wiehle et al. (2013, 2014) observed that after stopping enclomiphene, testosterone levels remained elevated for approximately one week — despite enclomiphene having only a 7-hour half-life. The drug was gone. The testosterone elevation persisted.
This "legacy effect" was seen even after only two weeks of dosing. The most plausible explanation: enclomiphene doesn't just temporarily remove estrogen feedback. It appears to restore the natural pulsatile pattern of LH/FSH secretion, and once that rhythm is re-established, it sustains itself for a period even without the drug.
This connects directly to my earlier article on the kisspeptin paradox. The HPG axis runs on pulses — KNDy neurons fire in bursts, GnRH is released in waves, LH follows in synchronized spikes. In secondary hypogonadism, these pulses are blunted. Enclomiphene, by removing excessive estrogen-mediated negative feedback, may allow the pulse generator to resume its natural rhythm.
If this is correct, enclomiphene is doing something fundamentally different from simply blocking a receptor. It's restoring a dynamic pattern — the endogenous oscillation that drives the entire axis. And once that pattern is running, it has inertia.
Whether this legacy effect is clinically meaningful — could men take enclomiphene intermittently rather than daily? — remains untested. But the observation resonates with everything we know about how the HPG axis actually functions.
Safety: What We Know and Don't Know
Enclomiphene's safety profile appears meaningfully better than clomiphene's, but the long-term data is thin. Here's an honest accounting.
Risks Associated with CC (Likely Zuclomiphene-Driven)
What We Don't Have for Enclomiphene
- No long-term bone density data in men — estrogen is important for male bone health. Blocking estrogen signaling chronically could theoretically impair bone metabolism. No study has measured this.
- No cardiovascular outcome studies — the TRAVERSE trial provided CV safety data for TRT. No equivalent exists for enclomiphene.
- No polycythemia data — TRT raises hematocrit. Enclomiphene raises endogenous T — does it cause polycythemia to the same degree? Unknown.
- Most studies are under one year — the longest controlled data is from the Androxal Phase 3 trials. Real-world use now extends years for many patients, but formal long-term safety monitoring is absent.
The ICSM 2024 consensus endorsed enclomiphene but with an honest caveat: safety data is limited. The 82% reduction in adverse events compared to CC is encouraging but comparative — it doesn't establish absolute long-term safety.
Who Responds — and Who Doesn't
SERMs don't work equally well for everyone. The ICSM 2024 meta-regression identified two key modifiers:
- Age: Older men show reduced SERM benefit. This aligns with the known age-related multi-site HPG axis deterioration — reduced GnRH output, attenuated LH efficacy (2.7x less in older men per Veldhuis), and increased feedback sensitivity. If the downstream machinery is impaired, removing feedback inhibition at the pituitary can only do so much.
- BMI: Higher BMI reduces SERM response. Obesity drives multiple HPG suppression mechanisms — leptin resistance, inflammatory cytokines, excess aromatase activity — that overwhelm the benefit of estrogen receptor blockade alone. For severely obese hypogonadal men, weight loss may be the more effective intervention.
The ideal enclomiphene responder is the younger man with functional secondary hypogonadism — intact testes, working pituitary, but a dysregulated feedback loop. The man whose hypothalamus is being over-suppressed by estrogen feedback. Remove that brake, and the axis runs.
Men with primary hypogonadism (testicular failure) won't respond to any SERM — there's no signal that can make damaged testes produce more testosterone. Men with organic pituitary disease (tumors, infiltrative lesions) also won't respond, because the pituitary can't increase LH/FSH even when feedback is removed.
There's also the discontinuation reality. Clomiphene discontinuation studies show that 78% of men fall below the testosterone threshold within 3 months, and all return to pre-treatment baseline by 6 months. This is consistent with what I've discussed in my article on hCG and axis recovery: organic secondary hypogonadism appears to be a chronic condition. The drugs work while you take them. They don't cure the underlying dysfunction.
The legacy effect offers a sliver of nuance — there may be a brief period of sustained pulsatility after stopping. But the trajectory is clear.
Access: The Current Landscape
Enclomiphene exists in a regulatory gray zone. It is not FDA-approved for any indication in men. It is not a scheduled substance. It is the pharmacologically active isomer of an FDA-approved drug (clomiphene).
In practice, enclomiphene is available in the United States through:
- Compounding pharmacies — under Section 503A of the FD&C Act, compounding pharmacies can prepare enclomiphene from bulk pharmaceutical ingredient with a valid prescription. The FDA's Pharmacy Compounding Advisory Committee (PCAC) voted against including enclomiphene on the 503A Bulks List in June 2022, but compounding continues because enclomiphene is a component of approved clomiphene.
- Telehealth platforms — services like Hims, Maximus, and others now prescribe enclomiphene for male hypogonadism, typically pairing it with lab monitoring. This has dramatically expanded access.
The legal situation is stable but uncertain. Without FDA approval as a standalone product, enclomiphene's availability depends on the compounding pharmacy regulatory framework — which could change. The British Society for Sexual Medicine (BSSM) has issued a position statement supporting enclomiphene use, providing additional clinical legitimacy.
Where This Fits
Enclomiphene occupies a specific and valuable position in the secondary hypogonadism treatment landscape. It is not TRT. It is not a cure. It is an axis-preserving intervention that works with the body's endogenous production.
For the right patient — younger, functional hypogonadism, desires fertility or wants to preserve endogenous production — enclomiphene is arguably the most practical pharmacological option available today. It's oral, once-daily, well-tolerated, and keeps the axis running. It doesn't have the delivery complexity of pulsatile GnRH pumps, the injection burden of hCG, or the axis-suppressing consequences of TRT.
The tragedy is that it should have been an approved medication by now. Instead, it exists in a compounding pharmacy gray zone — effective, supported by consensus guidelines, but lacking the regulatory stamp that would make it standard of care. The best version of a commonly used drug, available but not officially sanctioned.
For men currently on clomiphene who are experiencing mood, libido, or other side effects despite rising testosterone numbers: the pharmacology suggests it's not you. It's the zuclomiphene. Ask your provider about enclomiphene.
Key References: Helo et al., BJU Int 2017 (zuclomiphene:enclomiphene 20:1 ratio); Miller et al., JCEM 2019 (ZUC persistence >261 days); Wiehle et al., BJU Int 2013 & J Men's Health 2014 (enclomiphene efficacy, legacy effect); 2025 meta-analysis, Archives of Endocrinology and Metabolism (10 RCTs, 819 patients, TT +273.76 ng/dL); ICSM 2024 consensus, Sexual Medicine Reviews Oct 2025 (enclomiphene preferred, 82% fewer AEs); Saffati et al., Translational Andrology and Urology 2024 (Baylor safety comparison); Habous et al. (CC vs hCG vs combination, n=282); Repros Therapeutics Androxal regulatory filings 2015–2021.